Gonadorelin Protocol: Complete Cycling & Dosing Guide

Gonadorelin Protocol: Complete Cycling & Dosing Guide

Overview

Gonadorelin is a synthetic gonadotropin-releasing hormone (GnRH) that mimics the body's natural signaling to the pituitary gland. Unlike many hormonal compounds that suppress your natural production, gonadorelin's primary clinical use is to preserve and restore endogenous hormone production—making it distinctly different from traditional hormone replacement.

The critical factor with gonadorelin is pulsatility. The body releases GnRH in specific pulses throughout the day. When administered in this pulsatile manner, gonadorelin stimulates LH and FSH release, which drives testosterone production in men and supports reproductive function in both sexes. Continuous dosing, by contrast, causes receptor downregulation and the opposite effect—suppression of gonadotropins.

This guide focuses on practical, evidence-based protocols for gonadorelin use, with emphasis on the distinction between pulsatile (therapeutic) and continuous (suppressive) dosing.

Standard Protocol

Pulsatile Injectable Protocol (Most Effective for Testosterone Preservation)

The most researched and clinically validated approach uses subcutaneous injection:

• Dose: 100–250 mcg per injection
• Frequency: Twice weekly (e.g., Monday and Thursday)
• Route: Subcutaneous injection
• Typical cycle length: 12–16 weeks continuous use, then reassess
• Storage: 2–8°C (refrigerated); protect from light

Pulsatile Nasal Protocol (Alternative)

• Dose: 400–800 mcg per dose
• Frequency: 3 times daily
• Route: Intranasal
• Cycle length: 12–16 weeks continuous
• Advantage: Non-invasive; disadvantage: less consistent absorption and lower bioavailability compared to injection

Injectable is the standard for hormonal restoration protocols due to superior bioavailability and predictable peak-and-trough cycling.

Goal-Specific Protocols

Protocol 1: Testosterone Preservation During TRT/AAS Cycles

Objective: Maintain testicular size and endogenous LH/FSH signaling while on exogenous testosterone.

• Gonadorelin dose: 100 mcg subcutaneous
• Frequency: 2x weekly (e.g., Monday AM, Thursday AM)
• Timing relative to testosterone: Begin gonadorelin simultaneously with testosterone initiation
• Cycle length: Continue throughout TRT duration; no breaks required
• Expected LH/FSH response: LH should rise 2–4 fold within 30–60 minutes post-injection; FSH response slower (hours to days)

Rationale: Exogenous testosterone suppresses endogenous LH via negative feedback, which shuts down Leydig cell signaling. Pulsatile gonadorelin bypasses this negative feedback and maintains the LH signal needed to preserve testicular Leydig cell function and spermatogenesis.

Protocol 2: Restoration of Fertility in Hypogonadotropic Hypogonadism

Objective: Restore spermatogenesis and fertility in men with low LH/FSH due to hypothalamic dysfunction.

• Gonadorelin dose: 100–200 mcg subcutaneous
• Frequency: 2x weekly
• Cycle length: 12–24 weeks (spermatogenesis typically appears at 6 months; median time to full recovery is 12–18 weeks)
• Monitoring: Semen analysis at weeks 12, 16, 20; testosterone and FSH levels at weeks 4, 8, 12
• Dose escalation: If FSH/LH response is inadequate after 4 weeks, increase to 150 mcg 2x weekly; if still inadequate after 8 weeks, increase to 250 mcg 2x weekly

Expected timeline: Sperm motility appears by week 12–16; full spermatogenesis by week 20–24 in most cases.

Protocol 3: Secondary Hypogonadism Recovery (Post-Cycle Therapy)

Objective: Accelerate recovery of natural testosterone production after AAS cessation.

• Gonadorelin dose: 100 mcg subcutaneous
• Frequency: 2x weekly
• Start timing: Begin on day 1 after last AAS injection (for long-esters, begin 5–7 days after final injection)
• Duration: 8–12 weeks
• Stack: Often combined with SERMs (selective estrogen receptor modulators); gonadorelin dose remains unchanged

Rationale: Gonadorelin provides direct pituitary stimulation to LH/FSH release independent of SERM action, accelerating the recovery of the hypothalamic-pituitary-testicular axis.

How to Administer Step-by-Step

Reconstitution (if using lyophilized powder):

1. Remove gonadorelin vial and bacteriostatic water from refrigeration; allow to reach room temperature (5 minutes)
2. Swab rubber septum of gonadorelin vial with alcohol pad; allow to dry
3. Draw bacteriostatic water volume per manufacturer instructions (typically 1–2 mL)
4. Inject water slowly into gonadorelin vial
5. Gently swirl (do not shake vigorously) for 30–60 seconds until completely dissolved
6. Solution should be clear and colorless; discard if cloudy
7. Label vial with reconstitution date; use within 24–48 hours if stored at room temperature, up to 14 days if refrigerated

Injection Administration:

1. Wash hands with soap and water
2. Choose injection site: abdomen (2 inches from navel), outer thigh, or upper arm; rotate sites with each injection
3. Swab skin with alcohol pad; allow to dry completely (5–10 seconds)
4. Pinch a fold of skin with non-dominant hand
5. Insert needle at 45–90 degree angle using a 28–31 gauge needle (0.5–1 inch length)
6. Inject slowly over 5–10 seconds
7. Withdraw needle; apply light pressure with clean gauze for 10 seconds
8. Do not massage injection site

Nasal Administration (if using nasal formulation):

1. Clear nasal passages gently
2. Tilt head back slightly
3. Insert nozzle into nostril and spray dose; one nostril for dose, alternate nostrils with subsequent doses
4. Keep head tilted back for 30 seconds post-administration
5. Do not sniff or blow nose for 15 minutes

Cycle Example: Week-by-Week Schedule

12-Week Testosterone Preservation Cycle (Concurrent with TRT)

12-Week Post-Cycle Recovery Cycle (After 16-Week AAS Cycle)

What to Expect: Timeline of Effects

Within 24 hours:

• Transient flushing and warmth at injection site (most common side effect, mild)
• Possible mild headache

Days 2–7:

• LH spike visible on blood tests (typically 2–4x above baseline)
• FSH begins gradual rise (slower kinetics than LH)
• Mild increase in libido in responders
• Possible mild nausea or lightheadedness (rare, transient)

Weeks 2–4:

• FSH and testosterone begin to rise (if on preservative protocol) or normalize (if on recovery protocol)
• Testicular sensitivity to LH stimulation improves
• Sperm production begins (if FSH elevation is adequate)

Weeks 4–8:

• Testosterone levels plateau at expected steady-state
• Testicular size stabilization (should not atrophy if dosing adequate)
• Spermatogenesis accelerates; visible improvements on semen analysis by week 8

Weeks 8–12:

• Full gonadal recovery (spermatogenesis, testosterone, testicular volume) in most responders
• LH/FSH values sustain with continued twice-weekly dosing

Week 12 onward:

• If protocol continues (e.g., ongoing TRT), no further changes expected; steady-state maintained
• If protocol ends, gonadorelin discontinuation does not cause rebound suppression

Common Protocol Mistakes

Mistake 1: Continuous High-Dose Administration

Many users confuse gonadorelin with GnRH agonists used in prostate cancer (goserelin, triptorelin), which are given as continuous-release injections designed to suppress testosterone via receptor downregulation. Using gonadorelin continuously at high doses or as a single weekly large dose paradoxically causes suppression, not stimulation.

Correction: Strict adherence to pulsatile dosing (twice weekly at 100–250 mcg, or three times daily nasal) is mandatory.

Mistake 2: Inadequate Dose for Body Weight

Lean body mass influences GnRH receptor density and gonadotropin sensitivity. Users under 160 lbs may respond to 75–100 mcg; those over 220 lbs may need 150–250 mcg.

Correction: Start at 100 mcg and assess LH response via labs at week 4. If LH is not elevated 2–3 fold, increase to 150 mcg; repeat assessment.

Mistake 3: Insufficient Cycle Length

Spermatogenesis takes 12–16 weeks to fully mature. Discontinuing gonadorelin at week 4 or 6 leaves the process incomplete.

Correction: Minimum 12 weeks for fertility protocols; 8–12 weeks for preservation protocols concurrent with TRT.

Mistake 4: Mixing Injectable and Nasal in Same Week

This creates unpredictable pulsatile patterns and dose stacking.

Correction: Choose one route and maintain consistency throughout the cycle.

Mistake 5: Using Gonadorelin During Suppressive TRT Without Knowledge

Some compounded TRT prescriptions include gonadorelin with no disclosure. High-dose testosterone suppresses endogenous LH; gonadorelin then becomes ineffective due to testosterone's negative feedback.

Correction: Gonadorelin is most effective at baseline or low testosterone levels. If using high-dose exogenous testosterone, gonadorelin can maintain testicular size but cannot restore endogenous testosterone.

How to Stack with Other Compounds

Stack 1: Gonadorelin + TRT (Testosterone Preservation)

• Gonadorelin: 100 mcg 2x/week subcutaneous
• Testosterone: Dose as prescribed (typically 50–100 mg/week)
• No interaction; administered independently
• Expected benefit: Testicular size preservation, maintenance of spermatogenesis (if semen quality baseline acceptable)

Stack 2: Gonadorelin + SERM (Post-Cycle Recovery)

• Gonadorelin: 100 mcg 2x/week subcutaneous
• Tamoxifen: 40 mg/day weeks 1–4, taper to 20 mg/day weeks 5–8, off by week 12
• OR Clomiphene: 100 mg/day weeks 1–8, taper to 50 mg/day weeks 9–12
• Rationale: Complementary mechanisms—gonadorelin drives pituitary LH/FSH release; SERM blocks estrogen-mediated negative feedback. Combined effect accelerates recovery.
• Timing: Begin both simultaneously on day 1 post-AAS
• Expected benefit: Faster testosterone recovery (weeks 4–8 vs weeks 8–12 with SERM alone)

Stack 3: Gonadorelin + hCG (Hybrid Approach)

• Gonadorelin: 100 mcg 2x/week subcutaneous
• hCG: 500–1000 IU 2–3x/week intramuscular or subcutaneous
• Rationale: hCG directly stimulates Leydig cells (mimics LH); gonadorelin stimulates pituitary. Synergistic effect on testicular testosterone production.
• Note: This is less common in clinical practice; typically used in specialized fertility protocols.
• Expected benefit: Faster spermatogenesis recovery and higher testosterone levels than gonadorelin monotherapy

Stack 4: Gonadorelin + FSH (Fertility Restoration)

• Gonadorelin: 100 mcg 2x/week subcutaneous
• Recombinant FSH: 75–150 IU 3x/week intramuscular or subcutaneous
• Indication: Severe spermatogenic arrest or very low baseline FSH
• Rationale: Pulsatile GnRH drives endogenous FSH; exogenous FSH supplements if endogenous response is inadequate
• Expected benefit: Spermatogenesis induction in 80–90% of cases within 16 weeks

Protocol Quick Reference

Signs It's Working

Optimal response indicators:

• LH elevation 2–4 fold above baseline within 24 hours of injection (confirmed via labs)
• FSH rise beginning by week 2–4 (gradual, cumulative effect)
• Testosterone stabilization or rise by week 4–8 (depending on baseline)
• Testicular volume maintained or increased (clinical palpation or ultrasound)
• Semen analysis improvement: increased motility (week 8–12), increased count (week 12–16)
• Subjective improvement in libido and energy within 2–4 weeks (variable)

Inadequate response indicators (requiring dose adjustment):

• LH does not rise 2x above baseline